Oxidative stress as a therapeutic target for the prevention and treatment of early age-related macular degeneration

Surv Ophthalmol. 2021 May-Jun;66(3):423-440. doi: 10.1016/j.survophthal.2020.09.002. Epub 2020 Sep 19.

Abstract

Age-related macular degeneration, the leading cause of irreversible visual loss among older adults in developed countries, is a chronic, multifactorial, and progressive disease with the development of painless, central vision loss. Retinal pigment epithelial cell dysfunction is a core change in age-related macular degeneration that results from aging and the accumulated effects of genetic and environmental factors that, in part, is both caused by and leads to oxidative stress. In this review, we describe the role of oxidative stress, the cytoprotective oxidative stress pathways, and the impact of oxidative stress on critical cellular processes involved in age-related macular degeneration pathobiology. We also offer targeted therapy that may define how antioxidant therapy can either prevent or improve specific stages of age-related macular degeneration.

Keywords: age-related macular degeneration; aging; antioxidant therapy; oxidative stress.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aged
  • Aging
  • Antioxidants / therapeutic use
  • Humans
  • Macular Degeneration* / drug therapy
  • Macular Degeneration* / prevention & control
  • Oxidative Stress / physiology
  • Retinal Pigment Epithelium*

Substances

  • Antioxidants